A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: ABBV-453
DRUG: Daratumumab
DRUG: Dexamethasone
DRUG: Pomalidomide

Sponsor

AbbVie